ERBB2 and breast cancer: In addition, MAGI1 loss is associated with the acquired resistance to hormonal therapy in ER+ BC: low MAGI1 levels predict a more aggressive behavior, whereas high levels correlate with a lower risk of relapse in ER+HER2− patients treated with tamoxifen compared with those who are untreated or who are chemotherapy-treated [21].